1. 190P Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale. (December 2022) Authors: Paturel, C.L.; Anceriz, N.; Eyles, J.; Lapointe, J-M.; Denis, C.; Breso, V.; Courtois, R.; Augier, S.; Brown, L.; Luheshi, N.; Watkins, A.; Cooper, Z.A.; Tu, E.; Vivier, E.; Fraenkel, P.G. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗